DP2 antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment
Increased airway smooth muscle mass, a feature of airway remodeling in asthma, is the strongest predictor of airflow limitation and contributes to asthma-associated morbidity and mortality. No current drug therapy for asthma is known to affect airway smooth muscle mass. Although there is increasing...
Main Authors: | Saunders, R, Kaul, H, Berair, R, Gonem, S, Singapuri, A, Sutcliffe, AJ, Chachi, L, Biddle, MS, Kaur, D, Bourne, M, Pavord, ID, Wardlaw, AJ, Siddiqui, SH, Kay, RA, Brook, BS, Smallwood, RH, Brightling, CE |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Association for the Advancement of Science
2019
|
Similar Items
-
Fevipiprant reduced airway smooth muscle massin asthmatics via PGD2Receptor antagonism
by: Saunders, R, et al.
Published: (2017) -
Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism
by: Saunders, R, et al.
Published: (2017) -
Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial
by: Gonem, S, et al.
Published: (2016) -
Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial.
by: Brightling, C, et al.
Published: (2000) -
Sputum eosinophilia in idiopathic pulmonary fibrosis.
by: Birring, S, et al.
Published: (2005)